araag2/HINT huggingface dataset:
Clinical trial NCT01474278 (phase 1, status: completed)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: placebo, ro5028442
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN(C)CCN1C=C(C(=O)N2CCC3(CC2)OCC2=CC=CC=C32)C2=CC=C(Cl)C=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of Autistic Disorder as defined by DSM-IV, confirmed by the
             team and supported with the Autistic Diagnostic Observation Schedule (ADOS)

          -  Male adults, 18 to 45 years of age

          -  IQ > 70 (Wechsler Adult Intelligence Scale-Full scale)

          -  Body mass index (BMI) 18 to 35 kg/m2 inclusive

          -  Aberrant Behavior Checklist (ABC) - Irritability subscale score </= 13

        Exclusion Criteria:

          -  Positive urine test for drugs of abuse

          -  Alcohol and/or substance abuse/dependence during the last 12 months

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  Clinically relevant cardiovascular, renal, hepatic or hematologic disease or disorder

          -  Active inflammatory pulmonary disease

          -  History of epilepsy/seizure disorder (except for simple febrile seizures)

          -  Initiation of new or major change in psychosocial intervention within 4 weeks prior to
             randomization

          -  Treatment with any investigational agent within 90 days prior to screening

          -  History of hypersensitivity or allergic reactions
Clinical trial NCT00368875 (phase 1/phase 2, status: completed)
Conditions: male breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer
ICD codes: C50.021, C50.022, C50.029, C50.121, C50.122, C50.129, C50.621, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: vorinostat, paclitaxel
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  histologically or cytologically confirmed adenocarcinoma of the breast; effective with
             version 2.2 (1/26/09), only patients with disease that is accessible to biopsy and
             consent to serial biopsy are eligible

          -  stage IV disease, locally recurrent inoperable chest wall disease; at least one
             bidimensional and/or unidimensional, measurable indicator lesion must be present
             (patients with only non-measurable disease are eligible for the phase I trial only);
             all sites of disease should be noted and followed

          -  ECOG performance status =< 1 (Karnofsky >= 70%)

          -  Absolute neutrophil count >= 1,500/ul

          -  Platelets >= 100,000/ul

          -  Total bilirubin within normal institutional limits

          -  AST(SGOT)/ALT(SGPT) =< 2.5 x institutional upper limit of normal

          -  PTT and either INR or PT < 1.5 x normal

          -  Creatinine within normal institutional limits OR creatinine clearance >= mL/min/1.73
             m^2 for patients with creatinine levels above institutional normal

          -  Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC)
             ratio; for UPC ratio > 0.5, 24-hour urine protein should be obtained and the level
             should be < 1000 mg for patient enrollment;

          -  LVEF must be at or above the lower institutional limit of the normal range (on MUGA or
             Echo obtained within 12 weeks of registration, or within 4 weeks of prior Herceptin)

          -  Not pregnant/lactating

        Exclusion criteria:

          -  chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
             prior to entering the study

          -  may not be receiving any other investigational agents.

          -  history of allergic reactions attributed to compounds of similar chemical or biologic
             composition to vorinostat or other agents used in the study (e.g., paclitaxel,
             bevacizumab, quinolones)

          -  uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.
Clinical trial NCT01339884 (phase 1/phase 2, status: completed)
Conditions: friedreich ataxia
ICD codes: G11.11
Drugs: resveratrol
SMILES: OC1=CC=C(\C=C\C2=CC(O)=CC(O)=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in
             intron 1 of the FXN gene

          -  Functional stage on the Ataxia subscale of the FARS of 1 or higher

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Active arrythmias or significant cardiac insufficiency

          -  Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment

          -  Use of amiodarone or other medications which may have clinically significant drug
             interactions that cannot be safely monitored
Clinical trial NCT00079339 (phase 1/phase 2, status: completed)
Conditions: untreated childhood brain stem glioma
ICD codes: F80.81, F84.3, F93.8, F93.9, R62.0, E71.520, F64.2
Drugs: tipifarnib
SMILES: CN1C=NC=C1[C@@](N)(C1=CC=C(Cl)C=C1)C1=CC2=C(C=C1)N(C)C(=O)C=C2C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed non-disseminated intrinsic diffuse brainstem glioma

          -  Karnofsky performance scale (KPS) (for > 16 yrs of age) or Lansky performance score
             (LPS) (for =< 16 years of age) => 50 assessed within two weeks prior to registration

          -  Prior/concurrent therapy:

               -  Chemo: No prior therapy allowed

               -  Radiation therapy (XRT): No prior therapy allowed

               -  Bone Marrow Transplant: None prior

               -  Anti-convulsants: Patients receiving EIACDs will not be eligible; however,
                  patients may switch from EIACDs to non-EIACDs and must then be on non-EIACDs for
                  a minimum of 7 days prior to registration

               -  Growth factors: Off all colony forming growth factor(s) > 2 weeks prior to
                  registration (G-CSF, GM-CSF, erythropoietin)

          -  Absolute neutrophil count >= 1,000/mm^3

          -  Platelets >= 100,000/mm^3 (transfusion independent)

          -  Hemoglobin >= 8 gm/dL (transfusion independent)

          -  Serum creatinine that is less than the upper limit of institutional normal for age or
             GFR > 70 ml/min/1.73m2

          -  Bilirubin =< 1.5 time upper limit of normal for age

          -  SGPT (ALT) and SGOT (AST) < 2.5 times institutional upper limit of normal

          -  Female patients of childbearing potential must have negative serum or urine pregnancy
             test; patient must not be pregnant or breast-feeding

          -  Patients of childbearing or child fathering potential must be willing to use a
             medically acceptable form of birth control, which includes abstinence, while being
             treated on this study

          -  Signed informed consent according to institutional guidelines must be obtained

        Exclusion Criteria:

          -  Patients must not have any significant medical illnesses that in the investigator's
             opinion cannot be adequately controlled with appropriate therapy or would compromise
             the patient's ability to tolerate this therapy; patients must not have any disease
             that will obscure toxicity or dangerously alter drug metabolism

          -  Patients with disseminated intrinsic diffuse brainstem glioma

          -  Patients taking enzyme-inducing anticonvulsant drugs

          -  Patients with known allergy to topical or systemic imidazoles (e.g., clotrimazole,
             ketoconazole, miconazole, econazole)

          -  Patients receiving any other anticancer or experimental drug therapy

          -  Patients with uncontrolled infection
Clinical trial NCT00288171 (phase 1/phase 2, status: withdrawn)
Conditions: hypertension, renal transplant
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: placebo, allopurinol
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, O=C1N=CN=C2NNC=C12
Reason stopped: 
    insufficient number of eligible subjects
  
Eligibility criteria:

        Inclusion Criteria:

        Males or females 6 to 18 years in age. Post-menarche females must have a negative urine
        pregnancy test.

        Renal transplant recipient taking cyclosporin.

        Weight greater than 20kg

        Parental or guardian consent and child subject assent (if appropriate)

        SBP or DBP greater than 95th percentile for age, gender and height

        Exclusion Criteria:

        Severe or poorly controlled hypertension as defined by SBP or DBP more than 20mmHg >95th
        percentile for age, gender and height on active therapy, on 2 or more antihypertensive
        medications or a history of hypertensive encephalopathy

        Taking azathioprine or another nucleoside analogue medication

        Currently receiving ACE-I or ARB medications

        Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary or
        renal disease: Schwartz Formula GFR less than 60ml/min/1.73m2 ALT/SGPT greater than 2 times
        the upper limit of normal* Hemoglobin less than 9 gm/dl WBC less than 3.000/mm3 Platelet
        count less than 100,000/mm3 *age-adjusted normal range, TCH laboratory

        A history of cardiomyopathy, clinically significant structural heart disease or
        atrioventricular conduction disturbance, sick sinus syndrome, clinically significant
        cardiac arrhythmia or symptoms of congestive heart failure

        Pregnant or lactating females

        Any other investigational drug use within 30 days of enrollment

        Parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant
        with the study procedures.
Clinical trial NCT01031953 (phase 1/phase 2, status: terminated)
Conditions: breakthrough nausea and vomiting, unspecified adult solid tumor, protocol specific
ICD codes: H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: fosaprepitant dimeglumine, systemic chemotherapy
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, FC1=CNC(=O)NC1=O
Reason stopped: 
    drug contract timelines and inadequate enrollment
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of cancer

          -  Scheduled to receive inpatient chemotherapy containing at least moderately emetogenic
             agents

               -  May be given for adjuvant, neoadjuvant, curative, or palliative intent

               -  May be given orally, IV, or by continuous infusion on ≥ 1 day

          -  Scheduled to receive 5-HT3 receptor antagonist antiemetic (e.g., ondansetron,
             granisetron, palonosetron, dolasetron mesylate, or dexamethasone with or without a
             benzodiazepine) on the day of chemotherapy

          -  Self-report of at least mild nausea (for which the patient feels needs rescuing) or
             moderate nausea (a score of ≥ 2 on a 4-point Likert scale) OR has had ≥ 1 episode of
             emesis since receiving chemotherapy

          -  No history of chronic nausea and/or vomiting (without chemotherapy), anticipatory
             nausea and/or vomiting, or emesis within 24 hours before chemotherapy

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

          -  Able to understand English

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No clinical evidence of current or impending bowel obstruction (i.e., tumor pressing
             on the bowel)

          -  No allergy or intolerance to study drugs

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior chemotherapy allowed

          -  No aprepitant as prophylaxis or rescue treatment during the current course of
             chemotherapy (other than as a part of study therapy)

          -  Not scheduled to receive a dopamine antagonist after chemotherapy
Clinical trial NCT00511472 (phase 1, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mk-0941, placebo, lantus insulin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female (of non-childbearing potential) between 18 to 70 years of age

          -  Diagnosed with Type 2 Diabetes and currently being treated with basal insulin

          -  Smokers may participate, but they are limited to 10 cigarettes per day while at the
             clinic and must follow clinic smoking rules

        Exclusion Criteria:

          -  History of Type 1 diabetes

          -  Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12
             weeks prior to study start

          -  History of severe hypoglycemia

          -  Allergic to insulin
Clinical trial NCT01700179 (phase 1, status: completed)
Conditions: chronic hepatitis c infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ach-0143102, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@H]12)C1=NC2=CC=C(C=C2N1)C1=CC2=CC=C1CCC1=CC=C(CC2)C(=C1)C1=CC=C2N=C(NC2=C1)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@@H](NC(=O)OC)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 18 years and older

          -  Clinical diagnosis of hepatitis C with genotype 1b

          -  Chronic hepatitis C treatment naive subjects

          -  IL28B genotype CC

          -  HCV RNA > 10000 IU/mL at screening

          -  Females must be willing to use two effective methods of contraception during dosing
             period and for six months after the last dose of ribavirin.

          -  Male patients must be willing to use an effective barrier method of contraception
             throughout the dosing period and for six months after the last dose of ribavirin.
             Males must agree to not donate sperm while enrolled in the study and for six months
             after the last dose of ribavirin.

          -  Willing to participate in all study activities and all study requirements.

        Exclusion Criteria:

          -  BMI>36

          -  Pregnant or nursing females

          -  Clinically significant laboratory abnormalities at screening

          -  Previous participation in a clinical trial with protease inhibitor and/or NS5A
             inhibitor

          -  HIV infection or other liver diseases

          -  Positive Hepatitis B Surface Antigen

          -  Liver cirrhosis

          -  Uncontrolled psychiatric disease

          -  Clinical evidence of chronic cardiac disease

          -  History of malignancy of any organ system within 5 years
Clinical trial NCT00372853 (phase 1, status: completed)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cp-675,206, su011248, cp-675,206, su011248
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven renal cell carcinoma with metastases

          -  Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1

        Exclusion Criteria:

          -  Prior treatment with more than one systemic therapy for metastatic renal cell
             carcinoma

          -  History of or known brain metastases, spinal cord compression or carcinomatous
             meningitis, or new evidence of brain or leptomeningeal disease on screening Computed
             Axial Tomography (CT) or Magnetic Resonance Imaging (MRI) scan
Clinical trial NCT01202266 (phase 1, status: terminated)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo, pf-05161704 or placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated on october 29, 2010 due to gastrointestinal adverse events.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and/or female (non-childbearing potential) subjects between the ages of
             18 and 55 years, inclusive

          -  Body Mass Index (BMI) of 24.5 to 35.5 kg/m2 and a total body weight >50 kg (110 lbs.)

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy).

          -  History of regular alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.

          -  History or evidence of habitual use of tobacco or nicotine containing products within
             3 months of screening or positive cotinine test at screening or Day -1.
Clinical trial NCT00703703 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: darifenacin, tolterodine, placebo
SMILES: NC(=O)C([C@@H]1CCN(CCC2=CC3=C(OCC3)C=C2)C1)(C1=CC=CC=C1)C1=CC=CC=C1, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy males and females ≥ 50 years

          -  Body mass index equal to or greater than 18.5 kg/m2 and less than 35.0 kg/m2

        Exclusion Criteria:

          -  Known or suspected allergy to tolterodine ER or darifenacin or their components

          -  Subjects with irregular day and night patterns such as night shift workers

          -  Significant medical problems know to affect heart rate (ie., hypertension,
             hypotension, history of heart failure, history of pulmonary disease, etc.)

          -  Medication with potential known to affect heart rate

          -  History of any malignancy within the past 5 years, with the exception of localized
             basal cell carcinoma of the skin

          -  Pregnant or nursing women

          -  Subjects with diseases such as urinary retention, gastric retention, uncontrolled
             narrow-angle glaucoma, severe renal insufficiency, etc.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01536665 (phase 1, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months prior to
             randomisation

          -  Body mass index (BMI) between 20.0 and 28.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Use of liraglutide or exenatide within 3 months of randomisation

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last
             12 months) or hypoglycaemic unawareness as judged by the trial physician or
             hospitalisation for diabetic ketoacidosis during the previous 6 months

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening
Clinical trial NCT01467414 (phase 1, status: terminated)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Reason stopped: 
    this trial was terminated due to low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female Japanese subject aged 20-70 years (both inclusive)

          -  Japanese passport holder

          -  Japanese-born parents

          -  Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months

          -  Treated with insulin for at least 3 months

          -  Body Mass Index (BMI) maximum 33.0 kg/m^2

          -  Glycosylated haemoglobin A1c (HbA1c) maximum 10.0%

          -  Fasting C-peptide below 1.0 nmol/L

        Exclusion Criteria:

          -  Use of oral antidiabetic drugs (OADs) and/or glucagon like peptide-1 (GLP-1) receptor
             agonists (exenatide, liraglutide) within 3 months prior to screening

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening

          -  Not able or willing to refrain from smoking and use of nicotine gum or transdermal
             nicotine patches during the inpatient period

          -  Supine blood pressure at screening (after resting for 5 min) minimum 180 mmHg for
             systolic and/or minimum 100 mmHg for diastolic